934 related articles for article (PubMed ID: 28286925)
1. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
Al-Salama ZT; Keating GM
Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib for the treatment of kidney cancer.
Abdelaziz A; Vaishampayan U
Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
[TBL] [Abstract][Full Text] [Related]
5. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; George DJ
BMC Cancer; 2021 Aug; 21(1):904. PubMed ID: 34364385
[TBL] [Abstract][Full Text] [Related]
6. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
Flaifel A; Xie W; Braun DA; Ficial M; Bakouny Z; Nassar AH; Jennings RB; Escudier B; George DJ; Motzer RJ; Morris MJ; Powles T; Wang E; Huang Y; Freeman GJ; Choueiri TK; Signoretti S
Clin Cancer Res; 2019 Oct; 25(20):6080-6088. PubMed ID: 31371341
[TBL] [Abstract][Full Text] [Related]
8. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
9. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Amzal B; Fu S; Meng J; Lister J; Karcher H
PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
[TBL] [Abstract][Full Text] [Related]
11. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
[TBL] [Abstract][Full Text] [Related]
12. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
13. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib Approved for Renal Cell Carcinoma.
Cancer Discov; 2016 Jun; 6(6):OF3. PubMed ID: 27150533
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Choueiri TK; Hessel C; Halabi S; Sanford B; Michaelson MD; Hahn O; Walsh M; Olencki T; Picus J; Small EJ; Dakhil S; Feldman DR; Mangeshkar M; Scheffold C; George D; Morris MJ
Eur J Cancer; 2018 May; 94():115-125. PubMed ID: 29550566
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
17. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.
Wiecek W; Karcher H
PLoS One; 2016; 11(6):e0155389. PubMed ID: 27271250
[TBL] [Abstract][Full Text] [Related]
19. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.
Edwards SJ; Wakefield V; Cain P; Karner C; Kew K; Bacelar M; Masento N; Salih F
Health Technol Assess; 2018 Jan; 22(6):1-278. PubMed ID: 29393024
[TBL] [Abstract][Full Text] [Related]
20. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.
Albiges L; Schmidinger M; Taguieva-Pioger N; Perol D; Grünwald V; Guemas E
Future Oncol; 2022 Mar; 18(8):915-926. PubMed ID: 34911359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]